Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 10/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.53 |
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27737279 | 0.86 | ALDH1A1 (0.54) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL8810711 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL30949568 | 0.79 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL16371393 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL30949495 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL17743398 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL29127005 | 0.79 | ALDH1A1 (0.58) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL22636765 | 0.78 | GAA (0.53) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL995959 | 0.77 | GAA (0.65) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL12750055 | 0.77 | ALDH1A1 (0.43) | ALDH1A1KDM4EMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2024-07-02 | — | — | US | disclosed |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-11-03 | — | — | US | disclosed |
| EP-3966196-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-03-16 | — | — | EP | disclosed |
| EP-3800183-A1 | UREA DERIVATIVES AS TRK-INHIBITING COMPOUNDS | ONO Pharmaceutical Co., Ltd. (JP) | 2021-04-07 | — | — | EP | disclosed |
| EP-3459935-B1 | UREA DERIVATIVE AS TRK-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020225569-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2020-11-12 | — | — | WO | disclosed |
| US-10765676-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-09-08 | — | — | US | disclosed |
| US-20190231777-A1 | Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-01 | — | — | US | disclosed |
| US-10300060-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| CN-101273038-A | Macrocylic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2008-09-24 | — | — | CN | disclosed |
| EP-1919898-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-05-14 | — | — | EP | disclosed |
| EP-1910347-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1881002-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1881001-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007017144-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007014922-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014922-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | ALDH1A1 2532/4885KDM4E 4409/4885MEN1 3400/4885 |
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | CHP1, ERAP1, QSOX1 | ALDH1A1 1477/4885KDM4E 1036/4885MEN1 3762/4885 |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | ERAP1, CHP1, QSOX1 | ALDH1A1 1546/4885KDM4E 1040/4885MEN1 4235/4885 |
| US-10300060-B2 | Trk-inhibiting compound | LTK, ROR1, TRPV1 | ALDH1A1 2491/4885KDM4E 2556/4885MEN1 4258/4885 |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | ERAP1, CHP1, QSOX1 | ALDH1A1 1431/4885KDM4E 1035/4885MEN1 3904/4885 |
| US-20190231777-A1 | Trk-INHIBITING COMPOUND | LTK, ROR1, TRPV1 | ALDH1A1 2491/4885KDM4E 2556/4885MEN1 4258/4885 |
| US-10765676-B2 | Trk-inhibiting compound | LTK, ROR1, TRPV1 | ALDH1A1 2491/4885KDM4E 2556/4885MEN1 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.